Pharmacokinetics of asundexian with combined CYP3A and P‐gp inhibitors and an inducer: Target in vitro and in vivo studies

Abstract

The presented studies confirmed that CYP3A4 and P-gp contribute to asundexian metabolism and excretion. Observed effects were in line with data from a previous mass balance study.